Regeneron Pharmaceuticals, Inc.
Compare market positioning with top industry peers
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$14.3B
Market Cap
$73.7B
Net Income
$4.5B
Employees
17,200
Regeneron Pharmaceuticals is functioning as one of the most productive biotechnology research engines in the world, extracting wildly recurring revenues from its portfolio of scientifically rigorous, first-in-class antibody therapies. Under CEO Leonard Schleifer, the biotech giant generated exactly $14.4 billion in revenue and maintains a $73.7 billion market cap with exactly 17200 employees. The financial narrative in 2026 is entirely defined by the post-Dupixent pipeline expansion; reinvesting extraordinary Dupixent atopic dermatitis profits, Regeneron extracts compounding research advantages by furiously advancing its differentiated oncology and ophthalmology antibody cocktail pipeline.
Revenue Trend Analysis
YoY Change
+1%
4-Year CAGR
-2.8%
Peak Year
2021
Trend
Consistent Growth
Regeneron Pharmaceuticals, Inc. has reported revenue across 5 fiscal years, compounding at -2.8% annually over 4 years. The most recent year saw a 1% increase versus the prior year. Revenue peaked in 2021 at $16.1B. Out of 4 reported periods, 3 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $14.3B | $4.5B | +1.0% |
| FY2024 | $14.2B | $4.4B | +8.3% |
| FY2023 | $13.1B | $4.0B | +7.8% |
| FY2022 | $12.2B | $4.4B | -24.3% |
| FY2021 | $16.1B | $8.1B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Regeneron Pharmaceuticals, Inc. reported approximately $14.4B in fiscal year 2025 with a team of 17,200 employees worldwide.
Regeneron Pharmaceuticals, Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology and pharmaceuticals is driven by steady cash generation and pricing power, enabling Regeneron Pharmaceuticals, Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Regeneron Pharmaceuticals, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/regeneron/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Regeneron Pharmaceuticals, Inc. reported $14B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/regeneron/financials" target="_blank" rel="noopener">CorpDigest — Regeneron Pharmaceuticals, Inc. financials</a></div>